Topvision Eye Specialist BhdXKLS:0332 +3.03%53 EBITDA Margin % is 23.82% as of Mar. 2026, which is 5% below its 10-year median of 25.07. GuruFocus rates XKLS:0332 with a GF Score™ of 53/100 and a GF Value™ of RM0.68 (Significantly Undervalued). The stock has 8 warning signs investors should review. Among 664 Healthcare Providers & Services companies, Topvision Eye Specialist Bhd ranks better than 83.89% on this metric.
Topvision Eye Specialist Bhd (XKLS:0332) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Topvision Eye Specialist Bhd EBITDA Margin % Related Terms
Topvision Eye Specialist Bhd EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Topvision Eye Specialist Bhd EBITDA Margin % Chart
XKLS:0332 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Topvision Eye Specialist Bhd's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Topvision Eye Specialist Bhd EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Topvision Eye Specialist Bhd's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Topvision Eye Specialist Bhd's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Topvision Eye Specialist Bhd (XKLS:0332) has a EBITDA Margin % of 23.82% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Topvision Eye Specialist Bhd and its competitors. This is near median its historical median of 25.07. Over the past decade, Topvision Eye Specialist Bhd's EBITDA Margin % has ranged from 18.75 to 32.19. According to the industry distribution chart, Topvision Eye Specialist Bhd ranks #107 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 16.1%.
Is Topvision Eye Specialist Bhd's EBITDA Margin % too high?
Topvision Eye Specialist Bhd's current EBITDA Margin % of 23.82% is near median its 10-year median of 25.07. Over the past 10 years, this metric has ranged from a low of 18.75 to a high of 32.19. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Topvision Eye Specialist Bhd's value of 23.82% is 133.3% above this industry median. Based on the distribution chart, Topvision Eye Specialist Bhd ranks #107 out of 664 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Topvision Eye Specialist Bhd has a GF Score™ of 53/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Topvision Eye Specialist Bhd's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Topvision Eye Specialist Bhd ranks #107 out of 664 companies for EBITDA Margin %. This places Topvision Eye Specialist Bhd in the top 16% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. Topvision Eye Specialist Bhd's value of 23.82% is 133.3% above this benchmark. Historically, Topvision Eye Specialist Bhd's own EBITDA Margin % has ranged from 18.75 to 32.19 over the past decade. While the company's 10-year median is 25.07 vs. the industry median of 10.21, Topvision Eye Specialist Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Topvision Eye Specialist Bhd's current EBITDA Margin % of 23.82% is 133.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Topvision Eye Specialist Bhd and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Topvision Eye Specialist Bhd's current EBITDA Margin % is 23.82%, which is near median its own 10-year median of 25.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Topvision Eye Specialist Bhd stock overvalued right now?
Based on GuruFocus' analysis, Topvision Eye Specialist Bhd (XKLS:0332) is currently considered Significantly Undervalued. The stock's GF Value™ is RM0.68, compared to a current price of RM0.17 — trading 75% below its estimated fair value. The current EBITDA Margin % is 23.82%, which is near median its 10-year median of 25.07 and 133.3% above the Healthcare Providers & Services industry median of 10.21. Topvision Eye Specialist Bhd's overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Topvision Eye Specialist Bhd (XKLS:0332), the current EBITDA Margin % is 23.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Topvision Eye Specialist Bhd (XKLS:0332) Overvalued in 2026?
Based on GuruFocus' analysis, Topvision Eye Specialist Bhd stock appears to be undervalued.
The current stock price of RM0.17 is trading 75% below its estimated GF Value™ of RM0.68.
GuruFocus considers Topvision Eye Specialist Bhd to be Significantly Undervalued.
Key valuation signals for XKLS:0332:
EBITDA Margin %: 23.82% (near median its 10-year median of 25.07)
GF Value™: RM0.68 vs. price of RM0.17 (75% below fair value)
Industry Position: 133.3% above the Healthcare Providers & Services median (#107 of 664)
No single metric tells the full story. See the XKLS:0332 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Topvision Eye Specialist Bhd is principally involved in the provision of ophthalmology services and related medical consultancy services. The company is also engaged in the marketing of eye supplements and health food products. The company derives a majority of its revenue from its ophthalmology services business, providing treatments for general as well as complex eye diseases. Geographically, it operates in Malaysia.
53GF Score
Get the complete analysis for XKLS:0332
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0332 has been successfully added to your 
